Role of Caelyx in second line treatment of ovarian cancer

The authors published their own experiences and results of Caelyx treatment based on 40 ovarian cancer patients treated in 9 different institutions. Patients had been treated with platinum based or platinum-taxol combination chemoterapy. Their average age was 57.2 years (35-80). The average time to...

Full description

Saved in:
Bibliographic Details
Published inMagyar onkologia Vol. 48; no. 1; p. 97
Main Authors Pulay, Tamás, Csömör, Sándor, Faluhelyi, Zsolt, Hernádi, Zoltán, Krommer, Károly, Mayer, Arpád, Szánthó, András, Szántó, István, Thurzó, László
Format Journal Article
LanguageHungarian
Published Hungary 2004
Subjects
Adult
Aged
Aged, 80 and over
Antibiotics, Antineoplastic - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Disease Progression
Doxorubicin - therapeutic use
Drug Administration Schedule
Female
Humans
Middle Aged
Ovarian Neoplasms - drug therapy
Retrospective Studies
Treatment Failure
Treatment Outcome
Online AccessGet more information

Cover

More Information
Summary:The authors published their own experiences and results of Caelyx treatment based on 40 ovarian cancer patients treated in 9 different institutions. Patients had been treated with platinum based or platinum-taxol combination chemoterapy. Their average age was 57.2 years (35-80). The average time to progression was 3.8 months (1-8). The effects of the therapy were assessed on 36 patients and the results were 3 CR, 8 PR, 7 SD and 18 PD. Summarised the Caelyx therapy caused improvement in 30.55% of the patients and stabilisation in 19.44%. Supportive therapy was needed in 8 cases.
ISSN:0025-0244